Latest news with #healthcaretechnology
Associated Press
2 days ago
- Health
- Associated Press
Breakthrough in Light Therapy: KouShiCare utilizes DWV™LLLT Technology to Treat Dry Eyes
HONG KONG, July 27, 2025 /PRNewswire/ -- KouShiCare, a leading innovator in healthcare technology, is proud to announce a groundbreaking advancement in the treatment of dry eye disease. The company's latest device harnesses the power of DWV™ Low-Level Laser Therapy (LLLT) technology, marking a significant step forward in light-based ocular care. Approximately 344 million people worldwide suffer from dry eye disease. This condition causes discomfort, blurred vision, and a significant decline in quality of life. Traditional treatments, like eye drops and medications, often offer only temporary relief and may not effectively address underlying gland dysfunction. KouShiCare's latest innovation, the LuminEyes Light Therapy Device, utilizes LLLT (Low-Level Light Therapy) and DWV™ LLLT (Dual-Wavelength Low-Level Light Therapy) technology to promote cellular metabolism and tissue repair. The LLLT uses low-power LEDs, no more than 100mW/cm², to deliver precise red or near-infrared light to biological tissues while preventing thermal damage. Additionally, by irradiating the eyelids and Meibomian glands with LEDs at 600nm (visible red light) ～ 900nm (near-infrared light), DWV™ LLLT stimulates ocular metabolism through PBM (photobiomodulation), harnessing biological regulatory effects to enhance eye health. Numerous research and clinical studies have demonstrated that Red Light Therapy effectively softens blocked Meibomian gland lipids, improves the tear film's lipid layer, alleviates dryness and the sensation of a foreign body, and enhances tear film stability. Compared to traditional treatments, it delivers more significant results while offering greater convenience and comfort. KouShiCare's commitment to innovation extends to user experience. The LuminEyes device is designed for ease of use, allowing patients to perform treatments comfortably at home. Key features include: The LuminEyes Light Therapy Device is now available exclusively through the KouShiCare online store, offering a limited-time introductory discount of 15%. Patients seeking an effective, safe, and user-friendly solution to dry eye symptoms are encouraged to explore the benefits of this innovative device. Visit us online for more details and purchase: View original content to download multimedia: SOURCE Koushicare
Yahoo
4 days ago
- Business
- Yahoo
2 Digital Healthcare Stocks Poised for a Breakout
Key Points Healthcare technology companies are transforming patient access and care delivery, creating massive addressable markets worth hundreds of billions of dollars. Digital-first platforms can scale rapidly without the infrastructure costs of traditional healthcare providers, enabling superior unit economics and profit margins. Regulatory challenges and competitive pressures create temporary volatility that often presents compelling entry points for long-term investors. 10 stocks we like better than Oscar Health › Wall Street loves to punish healthcare stocks for short-term stumbles while missing their revolutionary potential. The sector's reputation for regulatory complexity and unpredictable reimbursement changes has created a risk-averse investment environment that consistently undervalues companies building the future of American healthcare. This myopic view ignores a fundamental shift happening beneath the surface. Healthcare technology companies are dismantling decades-old barriers between patients and care, creating direct-pay models that bypass insurance bureaucracy entirely. While traditional healthcare stocks trade on Medicare Advantage enrollment growth and medical loss ratios (MLRs), these digital disruptors are building subscription-based businesses with software-like economics and massive total addressable markets. Two companies exemplify this transformation -- one sustaining strong profitability while navigating industry headwinds, the other riding explosive growth despite recent partnership drama. Both face meaningful risks that create entry opportunities for investors who understand the long-term digitization trends reshaping American healthcare. Oscar's profitable start meets cost pressures Oscar Health (NYSE: OSCR) built on its profitable start to 2025 with a strong first quarter, though emerging challenges in Q2 have tempered the momentum. The company reported $3 billion in revenue -- a 42% year-over-year increase -- and $275 million in net income, up from $177 million the previous year. This 55% profit growth underscores Oscar's scalable technology model, but investors should also consider recent indications of cost pressure and volatility. The company's MLR rose to 75.4% in the first quarter, still within industry norms but now expected to increase further, with full-year MLR guidance revised upward to 86% to 87% due to Q2 trends. This dramatic guidance revision signals significant cost headwinds that could pressure margins throughout the year. Oscar's differentiation lies in its digital-first infrastructure, built specifically for the digital age. Unlike legacy insurers, Oscar designed its operation around digital-first member engagement -- leveraging telemedicine, artificial intelligence (AI)-powered health assessments, and predictive analytics. This approach has enabled the company to serve approximately 2 million members while maintaining competitive administrative expense ratios. The +Oscar platform remains a compelling long-term opportunity, offering potential to license care navigation and engagement tools to third-party providers. While this strategy could create high-margin software revenue, monetization beyond internal use is still in early stages. Its success may prove essential as potential changes to Affordable Care Act subsidies introduce new uncertainties to the individual insurance market. Hims navigates explosive growth and regulatory crosswinds Hims & Hers Health (NYSE: HIMS) has delivered a dramatic performance through 2025, highlighting both the explosive potential and inherent risks of disruptive healthcare models. The stock reached an all-time high of $72.98 in February before encountering significant turbulence from regulatory scrutiny and partnership disputes. The company's underlying business growth remains exceptional despite headline challenges. First-quarter revenue surged 111% year over year to $586 million, while adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) nearly tripled to $91 million. More importantly, Hims & Hers expanded its subscriber base to 2.4 million customers -- a 38% increase -- with nearly 60% now using personalized treatment solutions that command premium pricing. However, the Novo Nordisk partnership termination in June caused a major decline in the stock. This dispute over Hims & Hers' continued sale of compounded weight-loss medications exposes the company's central vulnerability: regulatory dependence on legally gray areas of pharmaceutical compounding. Beyond weight management, Hims & Hers has systematically expanded into mental health, dermatology, and hormone replacement therapy -- with over 80% of 2024 revenue coming from non-GLP-1 sources. Each vertical leverages the company's direct-to-consumer infrastructure, creating cross-selling opportunities that increase customer lifetime value. Yet, this expansion strategy faces intensifying competition from well-funded digital health competitors and increasingly digital-savvy incumbents. Weighing the digital healthcare transformation The healthcare technology revolution creates compelling investment opportunities for investors who can tolerate regulatory uncertainty and competitive pressure in exchange for exposure to transformative business models. Oscar Health offers a mature, profitable approach to technology-enabled insurance with multiple avenues for margin expansion and revenue diversification. The company's established market position and strong balance sheet provide defensive characteristics, while its technology platform positions it to capture value from healthcare's digital transformation. Hims & Hers provides higher-risk, higher-reward exposure to the direct-pay healthcare revolution, where patients increasingly bypass insurance for convenient, affordable treatments. The company's ambitious 2030 targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA reflect management's confidence in expanding beyond specialty medications into comprehensive primary care services. Should you buy stock in Oscar Health right now? Before you buy stock in Oscar Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Oscar Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $641,800!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,023,813!* Now, it's worth noting Stock Advisor's total average return is 1,034% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 George Budwell has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Digital Healthcare Stocks Poised for a Breakout was originally published by The Motley Fool
Medscape
18-07-2025
- Health
- Medscape
Does AI Aid Rare Bone Fracture Detection in Children?
TOPLINE: In patients with osteogenesis imperfecta, artificial intelligence (AI) assistance improved the fracture detection accuracy of radiologists from 83.4% to 90.7%. However, radiologists performed better than AI when their standalone performance was considered. METHODOLOGY: In this study, researchers analysed 336 appendicular and pelvic radiographs of 48 children (mean age, 12 years) with genetically confirmed osteogenesis imperfecta. The ground truth was determined by a consensus opinion of two consultant paediatric radiologists who labelled acute and healing fractures with bounding boxes. Seven radiologists independently evaluated anonymised images in two rounds — the first round without AI and the second round with AI assistance. The AI tool provided bounding boxes for suspected fractures but did not distinguish acute from healing fractures. After both rounds were completed, the results from radiologists without AI assistance, radiologists with AI assistance, and the AI alone were compared against the ground truth by calculating the intersection between the bounding boxes. TAKEAWAY: AI demonstrated a per-examination accuracy of 74.8% (95% CI, 65.4%-82.7%), compared with the average radiologist performance of 83.4% (95% CI, 75.2%-89.8%). Radiologists using AI assistance improved their average accuracy per examination to 90.7% (95% CI, 83.5%-95.4%). AI support increased average radiologist per-image accuracy by 7.0% (from 84.6% to 91.6%) and per-fracture accuracy by 3.7% (from 76.3% to 80.0%). Per fracture, AI assistance lowered true and false positives while raising true and false negatives, boosting the accuracy by 3.7%, specificity by 10.0%, and positive predictive value by 7.2%. On average, radiologists changed their per-fracture decisions in 72 instances; 69% of those changes matched the AI's suggestion, and 64% improved accuracy. IN PRACTICE: "In conclusion, the results of this study suggest that AI assistance improves radiologists' performance in diagnosing fractures in children with OI [osteogenesis imperfecta], even if it is not specifically trained for this population," the authors of the study wrote. "Nevertheless, compared to radiologists, the standalone AI performance was worse, thus highlighting potential dangers of implementing the AI tool in an autonomous manner," they added. SOURCE: This study was led by Cato Pauling, University College London, London, England. It was published online on July 07, 2025, in European Radiology. LIMITATIONS: Researchers included repeat examinations from some patients over the study period, which may have introduced bias due to similarities in appearances. This study used only one commercially available AI model, despite multiple products being available in the market. Additionally, the lack of a control group of patients without bone fragility disorder made it challenging to objectively evaluate whether the AI tool performed less accurately in children with osteogenesis imperfecta. DISCLOSURES: This study received funding support from the National Institute for Health and Care Research. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
16-07-2025
- Business
- Yahoo
ZimVie (ZIMV) Announces the Launch of its RealGUIDE Software Suite and Implant Concierge Service in Japan
ZimVie Inc. (NASDAQ:ZIMV) is one of the best undervalued medical device stocks to buy now. On June 5, ZimVie Inc. (NASDAQ:ZIMV) announced the launch of its RealGUIDE Software Suite and Implant Concierge service in Japan. A medical professional working on a dental implant in an operating room. The launch of the service in the Japenese market provides dentists expanded access to a digital dental implant ecosystem that extends from implant planning to placement and offers vertically integrated, end-to-end solutions. Management reported that the dental implant market opportunity is significant in Japan, and the country is ZimVie Inc.'s (NASDAQ:ZIMV) largest market in the APAC region. RealGUIDE software is the first complete cloud-based solution of its kind, and offers dentists all they need for precise implant planning, restorative design, and surgical guides to deliver time, workflow, and cost efficiencies. Implant Concierge is a virtual outsourcing service that aims to simplify and streamline guided surgery and implant treatment planning. ZimVie Inc. (NASDAQ:ZIMV) manufactures, designs, and distributes medical devices and surgical instruments. The company's operations are divided into the Spine Products and Dental Products segments. While we acknowledge the potential of ZIMV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
National Post
04-07-2025
- Business
- National Post
WELL Health Announces Voting Results for Election of Directors
Article content VANCOUVER, British Columbia — WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the ' Company ' or ' WELL '), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that at its annual general meeting held June 30, 2025 (the ' Meeting '), all of the nominees for election as directors of the Company referred to in its notice of meeting and information circular dated May 28, 2025 for the Meeting were elected. Article content A total of 67,105,724 common shares representing 26.52% of the outstanding common shares of the Company were voted by proxy at the Meeting. Voting results for the election of directors at the Meeting were as follows: Article content Article content Article content The results of other matters considered at the Meeting are reported in the Report of Voting Results as filed on SEDAR+ ( filed on July 4, 2025. Article content WELL HEALTH TECHNOLOGIES CORP. Article content Per: 'Hamed Shahbazi' Article content Hamed Shahbazi Article content Chief Executive Officer, Chairman and Director Article content WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 210 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about the Company, please visit: Article content Article content Article content Article content Contacts Article content Article content Article content Article content
